NovoCure (NVCR) has drawn fresh attention after reporting first quarter 2026 revenue that exceeded expectations and raising its full-year revenue outlook to a range of US$690 million to US$710 million.

The strong Q1 update and higher 2026 revenue guidance have arrived alongside a sharp shift in sentiment, with a 62.61% 1 month share price return and a 65.98% 3 month share price return contrasting with a 3.50% 1 year total shareholder return decline. This suggests that momentum has only recently turned more positive.

If NovoCure’s rebound has you rethinking the sector, it may be a useful moment to scan other healthcare AI opportunities using our 35 healthcare AI stocks

With revenue guidance nudging higher, a wider loss, and the share price already up sharply in recent months, the key question now is whether NovoCure still trades at a discount or if the stock already reflects future growth.

Most Popular Narrative: 35.4% Undervalued

NovoCure’s most followed narrative sets a fair value of $26.07 per share versus the last close of $16.83, implying meaningful upside in that framework.

Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, likely driving topline revenue growth as global cancer incidence rises in the aging population.

Curious what justifies that higher fair value? The narrative focuses on accelerating revenue, a sharp margin shift, and a richer earnings multiple than the broader medical equipment space.

Result: Fair Value of $26.07 (UNDERVALUED)

However, the story can shift quickly if TTFields adoption disappoints, or if broad reimbursement and payer coverage take longer than expected to materialize.

Next Steps

With sentiment split between fresh optimism and clear risks, do not wait for others to decide for you. Weigh both sides by checking the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If NovoCure has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other compelling setups that could complement your view.

• Target potential mispricing by scanning 51 high quality undervalued stocks and see which stocks currently trade below what their fundamentals might justify.
• Strengthen income potential by reviewing 12 dividend fortresses that pair higher yields with a focus on resilience.
• Prioritise resilience by checking 72 resilient stocks with low risk scores built around companies with lower overall risk scores and steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.